Singular Genomics Announces 1-for-30 Reverse Stock Split

Core Viewpoint - Singular Genomics Systems, Inc. will implement a 1-for-30 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective June 26, 2024 [1][5]. Group 1: Reverse Stock Split Details - The reverse stock split will convert 30 shares of common stock into one new share, reducing the outstanding shares from approximately 74.7 million to about 2.5 million [6]. - No fractional shares will be issued; holders entitled to a fractional share will receive an additional fraction to round up to the next whole share [6]. - The reverse stock split will not affect the number of Series A Preferred Stock shares, which will remain at 2,500, but will adjust the conversion ratio proportionally [6][10]. Group 2: Company Overview - Singular Genomics is a life science technology company focused on next-generation sequencing and multiomics technologies, with products like the G4® Sequencing Platform and the upcoming G4X™ Spatial Sequencer [3]. - The company's mission is to empower researchers and clinicians to advance science and medicine [3]. Group 3: Administrative Information - Continental Stock Transfer & Trust Company will act as the exchange agent for the reverse stock split, providing stockholders with information regarding their ownership [2]. - The company plans to file an amendment to its certificate of incorporation with the Secretary of State of Delaware around June 25, 2024 [10]. - Additional information regarding the reverse stock split can be found in the definitive proxy statement and current report filed with the SEC [11].